READOUT // 05
Dosing in the literature, and why no validated blend dose exists
Animal studies report doses per body weight. There is no validated human dose for either constituent, and none for the combination.
BPC-157 TB-500 dosage in the research literature
BPC-157 TB-500 dosage is, in the published literature, a per-constituent and per-body-weight question — not a validated combination protocol. There is no validated dose for the blend. Commercial research labeling commonly pairs the two at fixed combined masses per vial (for example, ~10 mg + ~10 mg), but no peer-reviewed combination dose-finding study exists [16].
The BPC-157 component, in animal models only and not as human guidance, is frequently expressed at ~10 μg/kg and ~10 ng/kg; gastric-ulcer cytoprotection was studied at 400-800 ng/kg in rats [1][8]. The TB-500/Thymosin Beta-4 component spans a wide range — for example 2-18 mg/kg intraperitoneal in a rat embolic-stroke dose-response study, where the modeled optimum was near 3.75 mg/kg and 18 mg/kg gave no benefit [7]. That non-monotonic result matters: higher is not better, which directly undercuts "loading" rationales.
The described findings are preclinical and dosed per body weight in animals. They are summarized here as study facts, not as instructions for any human or any dose.
Half-life and reconstitution
On half-life and reconstitution: no validated human pharmacokinetic half-life exists for either constituent at research doses, and none for the blend. BPC-157's elimination half-life was reported as under 30 minutes in a rat/dog PK study [6]. Human IV Thymosin Beta-4 showed dose-proportional PK with half-life increasing at higher doses, but no specific half-life is established for the TB-500 heptapeptide itself [16].
Both constituents are supplied as lyophilized powders, reconstituted in bacteriostatic or sterile water and refrigerated for research handling [16]. Product identity, purity, and the actual BPC-157:TB-500 ratio in unregulated material are not guaranteed — a gap that compounds the existing TB-500 caveat that the fragment, not full-length Thymosin Beta-4, is what is sold [4].
Injection (subcutaneous / intramuscular) handling in research
The wolverine injection question concerns route. Subcutaneous and intramuscular are the predominant research-community routes for the blend, but those are not the routes of the controlled human efficacy trials — because no such combination trial exists [16]. The underlying rodent efficacy studies for both peptides predominantly used intraperitoneal administration [1][7].
Oral versus injectable routes in the research literature
On the BPC 157 TB 500 oral question: BPC-157 is studied as a "stable gastric" peptide and has been examined by peroral routes in animals [1]. Oral blend products are marketed, but they lack validated pharmacokinetics, and no controlled human study establishes oral bioavailability for the combination [16].
Across the underlying literature, the routes actually studied span several channels: intraperitoneal dominates the rodent efficacy work for both peptides [1][7]; intravenous appears in the human Phase 1 work on full-length Thymosin Beta-4 and a BPC-157 IV safety pilot [16]; and local, intra-lesional, and topical routes appear in individual-compound wound and tendon models [5]. The route a research community favors for the blend — subcutaneous or intramuscular — is therefore not the route most of the efficacy data were generated through, a mismatch worth naming alongside the absence of any combination trial.
A note on identity, purity, and the dose you cannot verify
One caveat sits underneath every dosing question for this blend. Because both constituents are distributed through non-regulated channels, product identity, purity, and the actual BPC-157:TB-500 ratio in a given vial are not guaranteed outside formal studies [16]. The TB-500 identity gap doubles here: the label says TB-500, but most of the efficacy literature it borrows from was generated with full-length Thymosin Beta-4, a different molecule of ~4963 Da versus the ~889 Da heptapeptide [4]. A printed 10 mg figure on a vial is a label, not a verified content — which is why this site treats blend "doses" as packaging conventions, never as validated quantities.